Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
Immunostimulatory agents used in cancer treatment often elicit serious toxicities, limiting their clinical application. Here, the authors show that the use of liposomes to intravenously deliver surface-anchored IL-2 and anti-CD137 proteins enables anti-cancer immunity and reduces the toxic side effe...
Enregistré dans:
Auteurs principaux: | Yuan Zhang, Na Li, Heikyung Suh, Darrell J. Irvine |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3d4040a0e60d452b9cad0c19ca4f203c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
par: Marta Compte, et autres
Publié: (2018) -
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
par: Daniela Schmid, et autres
Publié: (2017) -
Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response
par: Xiang Yu, et autres
Publié: (2020) -
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
par: Daniel S. Leventhal, et autres
Publié: (2020) -
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
par: Dobrin Draganov, et autres
Publié: (2021)